Skip to main content
Menu Close
Home
  • Register or Login
Home

Susan London

News

Survival of patients with mCRPC on hormone therapy differs by race

Author:
Susan London
Publish date: February 13, 2019

SAN FRANCISCO – An analysis of male veterans finds that African American men with chemotherapy-naive mCRPC treated with abiraterone or...

  • Read More

News

Pembrolizumab-axitinib nearly halves risk of death in RCC

Author:
Susan London
Publish date: February 12, 2019

SAN FRANCISCO – Pembrolizumab and axitinib combination therapy netted superior progression-free and overall survival relative to sunitinib in...

  • Read More

News

Radioligand is highly active in metastatic castrate-resistant prostate cancer

Author:
Susan London
Publish date: February 12, 2019

SAN FRANCISCO – Lutetium-177 PSMA-617 (LuPSMA) netted a high rate of PSA response and impressive overall survival among patients who had run out...

  • Read More

News

Pancreatic cancer expression signature is linked to chemoresistance

Author:
Susan London
Publish date: February 11, 2019

SAN FRANCISCO – Whole-genome and RNA sequencing of pancreatic cancers in the COMPASS trial has tied an RNA expression signature to poorer survival...

  • Read More

News

Gastrectomy does not alter benefit of new oral chemo in gastric cancer

Author:
Susan London
Publish date: January 30, 2019

SAN FRANCISCO – In the phase 3 TAGS trial, the gastrectomy subgroup did have higher rates of grade 3 or 4 adverse events.

  • Read More

News

Cancer vaccine fails in CRC but trial yields lessons

Author:
Susan London
Publish date: January 29, 2019

SAN FRANCISCO – Tecemotide did not improve recurrence-free or overall survival relative to placebo when given after R0/R1 resection of liver-only...

  • Read More

News

Dual BRAF, MEK inhibition proves highly active in biliary tract cancer

Author:
Susan London
Publish date: January 24, 2019

SAN FRANCISCO – Patients with BRAF V600E–mutated biliary tract cancer in a basket trial had a response rate of 42% when given the combination of...

  • Read More

News

mRECIST response to kinase inhibitors predicts survival in HCC

Author:
Susan London
Publish date: January 24, 2019

SAN FRANCISCO – Among patients with untreated HCC given first-line kinase inhibitors, those having a response based on mRECIST criteria lived...

  • Read More

News

Pembrolizumab bests chemo in PD-L1-positive esophageal cancer

Author:
Susan London
Publish date: January 23, 2019

SAN FRANCISCO – In KEYNOTE-181, second-line pembrolizumab reduced risk of death by 31% relative to chemotherapy among patients whose esophageal...

  • Read More

News

Age may dictate benefit of andecaliximab in gastric cancer

Author:
Susan London
Publish date: January 22, 2019

SAN FRANCISCO – Older adults appeared to derive both progression-free and overall survival benefit in the GAMMA-1 trial, which tested addition of...

  • Read More

News

COLOPEC: Adjuvant HIPEC for high-risk colon cancer disappoints

Author:
Susan London
Publish date: January 22, 2019

SAN FRANCISCO – Adding adjuvant oxaliplatin HIPEC to routine adjuvant systemic chemotherapy did not improve survival without peritoneal recurrence...

  • Read More

News

Young women opt for mastectomy even when neoadjuvant chemo works well

Author:
Susan London
Publish date: December 28, 2018

SAN ANTONIO – Although neoadjuvant chemotherapy doubled the proportion of women eligible for breast-conserving surgery, about 40% chose mastectomy...

  • Read More

News

Older breast cancer patients given adjuvant chemo live longer

Author:
Susan London
Publish date: December 27, 2018

SAN ANTONIO – Overall survival is better in breast cancer patients aged 65 years and older who receive adjuvant chemotherapy, although patients...

  • Read More

News

QOL is poorer for young women after mastectomy than BCS

Author:
Susan London
Publish date: December 18, 2018

SAN ANTONIO – A cohort study of 560 breast cancer survivors aged 40 or younger at diagnosis finds that breast satisfaction and several domains of...

  • Read More

News

Oxybutynin rapidly quells hot flashes

Author:
Susan London
Publish date: December 14, 2018

SAN ANTONIO - Oxybutynin reduced hot flash scores by at least two-thirds, improved measures of quality of life, and was safe and well tolerated in...

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »

We noticed you have an ad blocker enabled. Please whitelist us so we can continue to provide free content.

Whitelist MDedge.com
Close

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2019 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer and privacy policy.

click me
Menu Menu
  • Register or Login
Menu Close
Register or Login